BACKGROUND Valproic acid (VPA) is used to be an effective anti-epileptic drug and mood stabilizer. It has recently been demonstrated that VPA could promote neurite outgrowth, activate the extracellular signal regulated kinase pathway, and increases bcl-2 and growth cone-associated protein 43 levels in spinal cord. In the present research we demonstrate the effect of VPA on peripheral nerve rege...

Sin,—Hyperglycinsemia, hyperglycinuria,l propionicaciduria2 and Reye’s syndrome3 have been reported in epileptic patients taking the anticonvulsant drug valproic acid (VPA). While investigating possible mechanisms of VPA toxicity we found increased plasma glycine and propionic acid concentrations in symptom-free patients taking VPA (table i). With informed consent, loading tests with 500 ...

Valproic acid (VPA) is considered to be a drug of first choice for the therapy of generalized and focal epilepsies, including special epileptic syndromes. The drug is usually well tolerated, rare serious complications may occur in some patients, including hemorrhagic pancreatitis, coagulapathies, bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy. We report a case of VPA-ass...

Animals prenatally exposed to valproic acid (VPA), an antiepileptic agent, have been used as a model for autism spectrum disorders (ASDs). Previous studies have identified enhanced NMDA receptor (NMDAR) function in the brain of VPA rats, and demonstrated that pharmacological suppression of NMDAR function normalizes social deficits in these animals. However, whether repetitive behavior, another ...

A novel HPLC method for the determination of valproic acid (VPA) in human serum using nonanoic acid as internal standard (I.S.) is described in this article. The eluates were separated with a reverse phase column of the dimensions C18 250 × 4.6 mm internal diameter maintained at a temperature of 48 °C. A mobile phase consisting of acetonitrile and 29mM phosphate buffer (pH 3.5) 49: 51 v/v was u...

Valproic acid (VPA), an inhibitor of histone deacetylases, inhibits the growth of leukemia cells and induces their differentiation in vitro. In the present study, VPA in combination with two differentiating agents, 13-cis retinoic acid and 1,25-dihydroxyvitamin D3, was given to 19 previously untreated patients with MDS or CMML. Eight patients had to discontinue treatment before week 16 due to t...

objective(s) as there are conflicting findings regarding the clearance-dose and patient characteristics relationships for valproic acid (vpa), this study was conducted to investigate the relationship between patient demographic characteristics, vpa dosage and the drug clearance in adult iranian patients. materials and methods patients (n= 47) were either on monotherapy with vpa or were under co...

The traditional anti-convulsant drug Valproic Acid (VPA) has been found to be involved in suppressing cancer progression while modulating various cancer-associated signaling pathways. In particular, VPA acts as either a Histone Deacetylase (HDAC) inhibitor or a Notch signaling activator in suppressing tumor growth. VPA is less toxic, and by itself, has limited anti-tumor effects. Thus, VPA has ...

BACKGROUND There are limited studies on the effects of drugs that modulate epigenetic regulation for head and neck squamous cell carcinoma (HNSCC). This study determined the effect of valproic acid (VPA) on HNSCC. METHODS Growth inhibition effects of VPA alone or in combination with 5-aza-2'deoxycytidine (5-aza-dC) or all-trans retinoic acid (ATRA) was evaluated with MTT and clonogenic assays...